Please assess the completion status of the following clinical trial:

Trial Title: Radiographic and Clinical Outcomes of PureGen in Posterior Lumbar (PLIF) and Transforaminal Interbody Fusion (TLIF)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subjects with back and/or leg pain electing to receive Transforaminal Lumbar Interbody Fusion (TLIF)/ Posterior Lumbar Interbody Fusion (PLIF) procedure and posterior transpedicular stabilization with or without decompression at any level~* Unresponsive to conservative treatment for at least 6 months~* Radiographic confirmation of primary diagnosis~Exclusion Criteria:~* More than 2 levels requiring lumbar interbody fusion~* Spondylolisthesis greater than Grade I~* Prior failed fusion surgery at any lumbar level(s)~* Local or systemic infection past or present~* Active systemic disease~* Osteoporosis, osteomalacia, or other metabolic bone disease that would significantly inhibit bone healing~* BMI greater than 40~* Use of other bone graft, Bone Morphogenetic Protein (BMP) or bone graft substitutes in addition to or in place of those products specified~* Use of post operative Spinal Cord Stimulator (SCS)~* Any condition requiring postoperative medications that inhibit fusion, such as chronic use of oral or injected steroids or prolonged use of non-steroidal anti-inflammatory drugs~* Known or suspected history of alcohol and/or drug abuse~* Involved in pending litigation or worker's compensation related to the spine~* Pregnant or plans to become pregnant during the course of the study~* Insulin-dependent diabetes mellitus~* Known sensitivity to device materials~* Life expectancy less than duration of study~* Any significant psychological disturbance that could impair consent process or ability to complete self-assessment questionnaires~* Undergoing chemotherapy or radiation treatment~* Known history of hypersensitivity or anaphylactic reaction to dimethyl sulfoxide (DMSO)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lumbar Degenerative Disc Disease (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).